T1	Participants 64 81	glaucoma patients
T2	Participants 131 155	with two parallel groups
T3	Participants 332 377	patients with glaucoma or ocular hypertension
T4	Participants 612 693	total of 89 patients were enrolled, and 71 completed the 10-week treatment period
T5	Participants 1565 1615	patients with no contraindication to beta-blockers
